research
Research on GLP1 Signaling in the brain
How does GLP1 signal the brain? We take a look at related research to try and learn more.
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
GLP1s and Osteoarthritis
Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.
category:news
Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
category:side-effects
Semaglutide's link to blinding disease (NAION)
We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.
category:factsheet
Patent expirations for GLP1 Receptor Agonists
How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
category:news
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
category:news
Compounders sue FDA over Tirzepatide shortage changes
Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
category:news
Why the Tirzepatide shortage ending might be bad news.
Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.
category:news
GLP1s and Sleep Apnea
GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea
Habener, Mosjov and Knudsen win the Lasker award
The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.
category:news
Insurers continue to embrace Virtual Healthcare for GLP1s
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
categeory:watercooler
Novo's CEO will testify, but change is unlikely
Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.